Latest Allarity Therapeutics News & Updates

See the latest news and media coverage for Allarity. We track all announcements, press releases, and industry mentions in real time, all in one place.

Allarity Therapeutics (Allarity)

Clinical-stage precision medicine company for oncology

allarity.com

Headquarters: Tarpon Springs, United States
Founded year: 2012
Company type: Public company
Number of employees: 11–50
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Allarity Therapeutics (Allarity)

In short: Allarity advanced stenoparib with patents, CLIA certification, clinical data and $20M financing

Company announcements

August 14 Allarity

Allarity reports Q2 2026 results and milestones

It reports $26.9 million in cash, a patent through 2042, survival-linked DRP scores, CLIA certification, and Phase 3-ready stenoparib manufacturing.

July 7 Allarity

Allarity Therapeutics announces CLIA certification for DRP testing

It enables in-house biomarker testing for FDA registration trials.

June 30 Allarity

Allarity announces grant of key US patent for stenoparib DRP diagnostic

The patent extends protection into April 2042 and covers methods for selecting patients likely to benefit from stenoparib treatment.

May 15 Allarity

Allarity Therapeutics reports Q1 2026 results and clinical progress

Stenoparib development continues in small cell lung and ovarian cancers, with FDA Fast Track designation and new IP allowance.

Media coverage

Yesterday BioSpace

Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recur…

CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as ...

September 30 BioSpace

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - BioSpace

TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing...

September 14 Investing.com

Form 8K Allarity Therapeutics Inc For: 14 September By Investing.com

Form 8K Allarity Therapeutics Inc For: 14 September...

September 10 MarketWatch

Allarity Acquisition Corp. Files for IPO

Allarity Acquisition Corp. has filed for an initial public offering. The special-purpose acquisition company said it will sell 10 million units at $10 apiece, each...

Never miss news about Allarity

Track Allarity and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Allarity competitors & trending companies

Browse news for competitors to Allarity and other trending companies.